Objectives: Thrombosis and inflammation are associated with the pathogenesis of pulmonary arterial hypertension (PAH). However, there are no solid data supporting the involvement of platelet and leukocyte activation and interaction in PAH. The present study thus investigated the activation and interaction of circulating platelets and leukocytes in a rat model of monocrotaline (MCT)-induced pulmonary hypertension. Methods: Mean pulmonary arterial pressure (mPAP) was monitored in rats (n = 24) before and 2, 3 and 7 weeks after MCT (60 mg/kg)injection. In parallel, activation of circulating platelets and leukocytes and platelet-leukocyte aggregates were measured by whole-blood flow cytometry. Results: Two weeks after MCT injection, mPAP had increased significantly, i.e. from 11.25 ± 0.92 mm Hg at baseline to 15.71 ± 1.66 mm Hg (p < 0.05), and it had increased even further at week 7 (26.83 ± 3.29 mm Hg; p < 0.01). Fibrinogen binding of circulating platelets had increased from the basal level of 1.45 ± 0.61 to 4.08 ± 1.59% 3 weeks after MCT injection (p < 0.01). Platelet responsiveness to ADP was also significantly enhanced. CD11b expression of circulating neutrophils was elevated; i.e. mean fluorescence intensity increased from 1.67 ± 0.38 before MCT injection to 2.37 ± 0.31 3 weeks after MCT injection (p < 0.01), and N-formyl-methionyl-leucyl-phenylalanine (1 × 10–7M) stimulation induced more marked elevation of neutrophil CD11b expression in MCT-treated animals. Circulating platelet-neutrophil aggregates were already increased 2 weeks after MCT treatment (14.93 ± 4.22%; p < 0.01) compared to baseline (6.01 ± 2.91%) and remained elevated at 3 weeks (15.19 ± 4.78%; p < 0.01). Conclusions: MCT-induced PAH in rats is associated with increased platelet and leukocyte activation and platelet-leukocyte interaction in vivo, which may play an important role in the pathogenesis of PAH.

Keywords:
Monocrotaline, Platelets, Leukocytes, Platelet-leukocyte aggregates, Pulmonary arterial hypertension
1.
Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A: Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S–12S.
2.
Farber HW, Loscalzo J: Pulmonary arterial hypertension. N Engl J Med 2004;351:1655–1665.
3.
Chaouat A, Weitzenblum E, Higenbottam T: The role of thrombosis in severe pulmonary hypertension. Eur Respir J 1996;9:356–363.
4.
Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C, Garcia G, Simonneau G: Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001;22:451–458.
5.
Wolf M, Boyer-Neumann C, Parent F, Eschwege V, Jaillet H, Meyer D, Simonneau G: Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000;15:395–399.
6.
Berger G, Azzam ZS, Hoffman R, Yigla M: Chronic pulmonary hypertension – the monocrotaline model and involvement of the hemostatic system. Isr Med Assoc J 2009;11:376–379.
7.
Nakonechnicov S, Gabbasov Z, Chazova I, Popov E, Belenkov Y: Platelet aggregation in patients with primary pulmonary hypertension. Blood Coagul Fibrinolysis 1996;7:225–227.
8.
Ganey PE, Sprugel KH, White SM, Wagner JG, Roth RA: Pulmonary hypertension due to monocrotaline pyrrole is reduced by moderate thrombocytopenia. Am J Physiol 1988;255:H1165–H1172.
9.
Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L: Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249–254.
10.
Maeda NY, Carvalho JH, Otake AH, Mesquita SM, Bydlowski SP, Lopes AA: Platelet protease-activated receptor 1 and membrane expression of P-selectin in pulmonary arterial hypertension. Thromb Res 2010;125:38–43.
11.
Kato S, Sugimura H, Kishiro I, Machida M, Suzuki H, Kaneko N: Suppressive effect of pulmonary hypertension and leukocyte activation by inhaled prostaglandin E1 in rats with monocrotaline-induced pulmonary hypertension. Exp Lung Res 2002;28:265–273.
12.
Fartoukh M, Emilie D, Le Gall C, Monti G, Simonneau G, Humbert M: Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension. Chest 1998;114:50S–51S.
13.
Li N, Hu H, Lindqvist M, Wikstrom-Jonsson E, Goodall AH, Hjemdahl P: Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000;20:2702–2708.
14.
Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI: Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104:1533–1537.
15.
Hu H, Li N, Yngen M, Ostenson CG, Wallen NH, Hjemdahl P: Enhanced leukocyte-platelet cross-talk in Type 1 diabetes mellitus: relationship to microangiopathy. J Thromb Haemost 2004;2:58–64.
16.
Pamuk GE, Turgut B, Pamuk ON, Vural O, Demir M, Cakir N: Increased circulating platelet-leucocyte complexes in patients with primary Raynaud’s phenomenon and Raynaud’s phenomenon secondary to systemic sclerosis: a comparative study. Blood Coagul Fibrinolysis 2007;18:297–302.
17.
Schultze AE, Roth RA: Chronic pulmonary hypertension – the monocrotaline model and involvement of the hemostatic system. J Toxicol Environ Health B Crit Rev 1998;1:271–346.
18.
Wang HL, Zhang XH, Chang TH: Effects of tetrandrine on smooth muscle contraction induced by mediators in pulmonary hypertension. Acta Pharmacol Sin 2002;23:1114–1120.
19.
Hu H, Forslund M, Li N: Influence of extracellular calcium on single platelet activation as measured by whole blood flow cytometry. Thromb Res 2005;116:241–247.
20.
Li N, Hallden G, Hjemdahl P: A whole-blood flow cytometric assay for leukocyte CD11b expression using fluorescence signal triggering. Eur J Haematol 2000;65:57–65.
21.
Li N, Goodall AH, Hjemdahl P: Efficient flow cytometric assay for platelet-leukocyte aggregates in whole blood using fluorescence signal triggering. Cytometry 1999;35:154–161.
22.
Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F: Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811–2821.
23.
McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, Michelakis ED: Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 2004;95:830–840.
24.
Kereveur A, Callebert J, Humbert M, Herve P, Simonneau G, Launay JM, Drouet L: High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol 2000;20:2233–2239.
25.
Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Satoh T, Nakanishi N: Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000;102:2720– 2725.
26.
Hu H, Li N, Ekberg K, Johansson BL, Hjemdahl P: Insulin, but not proinsulin C-peptide, enhances platelet fibrinogen binding in vitro in Type 1 diabetes mellitus patients and healthy subjects. Thromb Res 2002;106:91–95.
27.
Janes SL, Wilson DJ, Chronos N, Goodall AH: Evaluation of whole blood flow cytometric detection of platelet bound fibrinogen on normal subjects and patients with activated platelets. Thromb Haemost 1993;70:659–666.
28.
Dorfmuller P, Perros F, Balabanian K, Humbert M: Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358–363.
29.
Kaplar M, Kappelmayer J, Veszpremi A, Szabo K, Udvardy M: The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy. Platelets 2001;12:419–422.
30.
Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K: Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003;9:61–67.
31.
Zarbock A, Singbartl K, Ley K: Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 2006;116:3211–3219.
32.
Otterdal K, Andreassen AK, Yndestad A, Oie E, Sandberg WJ, Dahl CP, Pedersen TM, Ueland T, Gullestad L, Brosstad FR, Aukrust P, Damas JK: Raised LIGHT levels in pulmonary arterial hypertension: potential role in thrombus formation. Am J Respir Crit Care Med 2008;177:202–207.
33.
Otterdal K, Smith C, Oie E, Pedersen TM, Yndestad A, Stang E, Endresen K, Solum NO, Aukrust P, Damås JK: Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes. Blood 2006;108:928–935.
34.
Damås JK, Otterdal K, Yndestad A, Aass H, Solum NO, Frøland SS, Simonsen S, Aukrust P, Andreassen AK: Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 2004;110:999–1005.
35.
Rose F, Hattar K, Gakisch S, Grimminger F, Olschewski H, Seeger W, Tschuschner A, Schermuly RT, Weissmann N, Hanze J, Sibelius U, Ghofrani HA: Increased neutrophil mediator release in patients with pulmonary hypertension – suppression by inhaled iloprost. Thromb Haemost 2003;90:1141–1149.
36.
Cirillo P, Golino P, Ragni M, Battaglia C, Pacifico F, Formisano S, Buono C, Condorelli M, Chiariello M: Activated platelets and leucocytes cooperatively stimulate smooth muscle cell proliferation and proto-oncogene expression via release of soluble growth factors. Cardiovasc Res 1999;43:210–218.
37.
Dorfmüller P, Zarka V, Durand-Gasselin I, Monti G, Balabanian K, Garcia G, Capron F, Coulomb-Lherminé A, Marfaing-Koka A, Simonneau G, Emilie D, Humbert M: Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:534–539.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.